The renin-angiotensin hypothesis for the pathogenesis of cardiac allograft vasculopathy

International Journal of Cardiology

Volumn 95, Issue 2-3, 2004, Pages 123-127

  Yousufuddin, Mohammed ^a   Yamani, Mohamad H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac allograft vasculopathy; Pathogenesis; Renin angiotensin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

ALLOTRANSPLANTATION; APOPTOSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CELL GROWTH; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENETIC PREDISPOSITION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOREGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASCULAR FIBROSIS; VASOMOTOR REFLEX;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; HEART TRANSPLANTATION; HUMANS; POSTOPERATIVE COMPLICATIONS; RENIN-ANGIOTENSIN SYSTEM;

EID: 2942552690     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.05.027     Document Type: Review

References (44)

1. Uretsky B.F., Murali S., Reddy P.S., et al. Development of coronary artery disease in cardiac transplant recipients recipients receiving immunosuppressive therapy with cyclosporine and prednisolone. Circulation. 76:1987;827-834
2. Ruiz-Ortega M., Lorenzo O., Ruperez M., et al. Role of renin-angiotensin system in vascular disease. Hypertension. 38:2001;1382-1391
3. Naftilan A., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1989;1424
4. Gibbons G.H., Pratt R.E., Dzau V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor beta-1 expression determines growth response to angiotensin II. J. Clin. Invest. 90:1992;461
5. Powell J., Clozel J.P., Muller R., et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;188
6. Strehlow K., Wassmann S., Bohm M., Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolemia. Ann. Med. 32:2000;386-389
7. Keidar S., Kaplan M., Hoffman A., et al. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis. 115:1995;201-215
8. Mehta J.L., Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J. Am. Coll. Cardiol. 39:2002;1429-1435
9. Hayek T., Aviram M., Heinrich R., Sakhnini E., Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem. Biophys. Res. Commun. 273:2000;417-420
10. Makaritsis K., Gavras H., Du Y., Chobanian A., Brecher P. Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotien E-deficient mice. Hypertension. 32:1998;1944-1948
11. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. Clin. Exp. Hypertens., A. 14:1992;307-331
12. Yusuf S., Sleight P., Pogue J., et al. Effects of angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart outcome prevention (HOPE) study investigators. N. Engl. J. Med. 342:2000;145-153
13. Ferrario C.M., Smith R., Levy P., Strawn W. The hypertension-lipid connection: insights into the relationship between angiotensin II and cholesterol in atherogensis. Am. J. Med. Sci. 323:2002;17-24
14. Beckman J., Creager M.A., Libby P. Diabetes and atherosclerosis. JAMA. 287:2002;2570-2581
15. van H.V., Ariapart P., Hoffstedt J., Lundkvist I., Bringman S., Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8:2000;337-341
16. Hainault I., Nebout G., Turban S., Ardouin B., Ferre P., Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am. J. Physiol. Endocrinol. Metab. 282:2002;E59-E66
17. Zhang S., Day I., Ye S. Nicotine induced changes in gene expression by human coronary artery endothelial cells. Atherosclerosis. 154:2001;277-283
18. Weis M., Pehlivanli S., Meiser B.M., von Scheidt W. Simvastatin treatment is association with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J. Am. Coll. Cardiol. 38:2001;814-818
19. Gaudin P., Rayburn B.K., Hutchins G.M., et al. Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am. J. Surg. Pathol. 19:1994;727-730
20. Yamani M.H., Haji S., Starling R.C., et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J. Am. Coll. Cardiol. 39:2002;978-980
21. Xu Y., Kumar D., Dyck J., et al. AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H1206-H1215
22. Gianello P., Fishbein J., Besse T., et al. Measurement of the vasoconstrictive substances endothelin, angiotensin II, and thromboxane B2 in cold storage solution can reveal ischemic insults. Transpl. Int. 7:1994;11-16
23. Graf K., Neuss M., Stawowy P., Hsueh W., Fleck E., Law R.E. Angiotensin II and alpha v beta 3 integrin expression in rat neonatal cardiac fibroblasts. Hypertension. 35:2000;978-983
24. Coker M., Jolly J., Joffs C., et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H543-H551
25. Fischer S., MacLean A., Liu M., Kalirai B., Keshavjee S. Inhibition of angiotensin converting enzyme by captopril: a novel approach to reduce ischemia-reperfusion injury after lung transplantation. J. Thorac. Cardiovasc. Surg. 120:2000;573-580
26. Vargas A., Robinson A.V., Schulak J.A. Captopril amelioration of renal reperfusion injury. J. Surg. Res. 57:1994;28-32
27. Shihab F., Bennett W., Tanner A., Andoh T.F. Angiotensin II blockade decreases TGF-beta 1 and matrix proteins in cyclosporin nephropathy. Kidney Int. 52:1997;660-673
28. Klahr S., Morrissey J. Angiotensin II and gene expression in kidney. Am. J. Kidney Dis. 31:1998;171-176
29. Shimada K., Yazaki Y. Binding sites for angiotensin II in human mononuclear leukocytes. J. Biomech. 84:1978;1013-1015
30. Gomez R., Norling L.L., Wilfong N., et al. Leukocytes synthesize angiotensinogen. Hypertension. 21:1993;470-475
31. Marrero M., Schieffer B., Paxton W., et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 375:1995;247-250
32. Bernstein K., Ali M., Sayeski P., Semeniuk D., Marrero M. New insights into cellular signaling of seven transmembrane receptors: the role of tyrosine phosphorylation. Lab. Invest. 78:1998;3-7
33. Duff J., Marrero M., Paxton W., Schieffer B., Bernstein K., Berk B.C. Angiotensin II signal transduction and mitogen activated protein kinase pathway. Cardiovasc. Res. 30:1995;511-517
34. Liu K., Gaffen S., Goldsmith M. Jak/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 10:1998;271-278
35. Weinstock J., Blum A., Kassab J. Angiotensin II is chemotactic for a T-cell subset which can express migration factor activity in murine schisosomiasis mansoni. Cell. Immunol. 107:1987;180-187
36. Kim J., Berliner J., Nadler J. Angiotensin II increases monocyte binding to endothelial cell. Biochem. Biophys. Res. Commun. 226:1996;862-868
37. Simon M., Weinstock J. Angiotensin II inhibition of mitogen-and antigen-induced human blood mononuclear cell thymidine uptake. J. Clin. Lab. Immunol. 18:1985;141-144
38. Foris G., Dezso B., Medgyesi G., Fust G. Effect of angiotensin II on macrophage function. Immunology. 48:1983;529-535
39. Yeung J. A comparison of the effect of angiotensin-converting enzyme inhibitors with bradykinin, angiotensin II, and their specific antagonist on concanavalin A-induced proliferation of mouse T-lymphocytes. Methods Find. Exp. Clin. Pharmacol. 16:1994;163-172
40. Nataraj C., Oliverio M., Mannon R., et al. Angiotensin II regulates cellular immune response through a calcineurin-dependent pathway. J. Clin. Invest. 104:1999;1693-1701
41. Kobayashi J., Crawford S., Backer C.L., et al. Captopril reduces graft coronary artery disease in a rat heterotropic transplant model. Circulation. 88:1993;286-290
42. Furukawa Y., Matsumori A., Hirozane T., Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserve graft status in murine model. A comparative study with captopril. Circulation. 93:1996;333-339
43. Cunningham D., Crisp S., Barbir M., Lazem F., Dunn M., Yacoub M. Donor ACE gene polymorphism: a genetic risk factor for accelerated coronary sclerosis following cardiac transplantation. Eur. Heart J. 19:1998;319-325
44. Pethig K., Heublein B., Hoffman A., Borlak J., Wahlers T., Haverich A. ACE gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J. Heart Lung Transplant. 19:2000;1175-1182